Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.04 · Expires 2036-06-04 | Direct | 35,152 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 35,152 · Balance 35,152 F1: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 21:12 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 35,152 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001193125-26-264019 · ownership.xml · derivative · entry 1 Incerti Carlo · CIK 0001915358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,152 Underlying: Common Stock · 35,152 shares Expires 2036-06-04 F1 · derivative.exercise_date: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| May 30, 2025 Filed Jun 4, 2025 01:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0000950170-25-081354 · ownership.xml · derivative · entry 1 Incerti Carlo · CIK 0001915358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 00:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 16,500 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0000950170-24-128176 · ownership.xml · derivative · entry 3 Incerti Carlo · CIK 0001915358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,693 Underlying: Common Stock · 16,500 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on March 2, 2022. The shares underlying the option are scheduled to vest over three years in equal monthly installments through March 2, 2025. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 00:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 16,500 | $28.73 | $474,045.00 |
DisclosureSEC source: 0000950170-24-128176 · ownership.xml · nonDerivative · entry 2 Incerti Carlo · CIK 0001915358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.47 to $29.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 00:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 16,500 | $8.69 | $143,385.00 |
DisclosureSEC source: 0000950170-24-128176 · ownership.xml · nonDerivative · entry 1 Incerti Carlo · CIK 0001915358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:10 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 25,133 | $0.00 Strike: $31.53 | $0.00 |
DisclosureSEC source: 0000950170-24-064727 · ownership.xml · derivative · entry 1 Incerti Carlo · CIK 0001915358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,133 Underlying: Common Stock · 25,133 shares Expires 2034-05-21 F1 · derivative.exercise_date: This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| May 24, 2023 Filed May 25, 2023 22:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 24,900 | $0.00 Strike: $13.49 | $0.00 |
DisclosureSEC source: 0001209191-23-032275 · doc4.xml · derivative · entry 1 Incerti Carlo · CIK 0001915358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2033-05-23 F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 23:23 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 39,193 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0001209191-22-016460 · doc4.xml · derivative · entry 1 Incerti Carlo · CIK 0001915358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,193 Underlying: Common Stock · 39,193 shares Expires 2032-03-01 F1 · derivative.exercise_date: The option was granted on March 2, 2022. The shares underlying the option are scheduled to vest over three years in equal monthly installments through March 2, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.